Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Ras mutational status is a biomarker for resistance to EGFR inhibitors in colorectal carcinoma.

Anticancer research - 1 Nov 2010

Dempke Wolfram C M, Heinemann Volker

Abstract excerpt

The epidermal growth factor receptor (EGFR) has been validated as a therapeutic target in several human tumours, including colorectal cancer (CRC). Although EGFR expression is used for patient selection, clinical experience shows that levels of EGFR expression (measured by immunohistochemistry) d...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Biomarkers, Tumor
Share to Colorectal Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to ErbB Receptors

Share to Mutation

Share to Prognosis

Share to ras Proteins

Source

Identifiers

PMID: 21115922

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-21115922-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Ras mutational status is a biomarker for resistance to EGFR inhibitors in colorectal carcinoma.PMID 21115922Read ↗

KRAS Mutations and Susceptibility to Cetuximab and Panitumumab in Colorectal CancerSemantic proximity Read ↗

KRAS mutations and sensitivity to anti-EGFR monoclonal antibodies in metastatic colorectal carcinoma: an open issue.Semantic proximity Read ↗

Oncogenic mutations as predictive factors in colorectal cancer.Semantic proximity Read ↗

The Emerging Role of NRAS Mutations in Colorectal Cancer Patients Selected for Anti-EGFR Therapies.Semantic proximity Read ↗

Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR.Semantic proximity Read ↗

RAS Mutations as Predictive Biomarkers in Clinical Management of Metastatic Colorectal Cancer.Semantic proximity Read ↗

Use of K-Ras as a predictive biomarker for selecting anti-EGF receptor/pathway treatment.Semantic proximity Read ↗

Prognostic and predictive value of K-RAS mutations in non-small cell lung cancer.Semantic proximity Read ↗

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.Semantic proximity Read ↗

The treatment of colorectal carcinoma with monoclonal antibodies: the importance of KRAS mutation analysis and EGFR status.Semantic proximity Read ↗

Predictive Molecular Markers of Response to Epidermal Growth Factor Receptor(EGFR) Family-Targeted TherapiesSemantic proximity Read ↗

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.